BOCA RATON, Fla., May 21, 2014 /PRNewswire/ --Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, announced today that it has opened its 15th U.S. plasma collection center. The 19,000 square foot state-of-the-art facility is located at 100 Business Park Way in Royal Palm Beach, Florida and will celebrate its official Grand Opening and ribbon cutting ceremony on May 21, 2014.
"We are very excited to announce the opening of our 15th plasma collection center, as well as our new national training facility," said Jordan Siegel, BPC's Chief Executive Officer. "This is the first of four new centers we expect to open this year as we continue to expand our U.S. operations to address the global demand for this very important source material."
The plasma collected at BPC's plasma centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas, such as BPC's BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] and Nabi-HB® [Hepatitis B Immune Globulin (Human)].
BPC has invested approximately $2.0 million in construction of this facility, which is designed for optimal efficiency and incorporates the newest donor screening technologies. The center will also be the national training and development facility for all of BPC's plasma sites. BPC expects to add approximately 50 new jobs to Royal Palm Beach's local economy and currently has career opportunities available for LPNs, RNs, phlebotomists and various other professional and administrative positions.
In addition to supporting the local economy through employment opportunities, the plasma center is actively recruiting local residents to donate plasma. Plasma donors not only contribute the source material for these plasma derived therapies that save the lives of thousands of patients but also are compensated for their donations.
The Royal Palm center is the third new facility BPC has opened in Florida within the last eleven months. The BPC Orlando plasma center, located at 2501 Discovery Drive in the Central Florida Research Park and adjacent to the University of Central Florida, opened its doors July of 2013; the Melbourne center, located at 3110 Lake Washington Road, opened October of 2013.
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, a German global provider of plasma therapies, researches, develops and manufactures biotherapeutic products with a specialization in immunology and hematology. BPC is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. The Company owns and manages fifteen plasmapheresis centers across the United States and astate-of-the-art manufacturing facility in Boca Raton, Florida. The Company employs more than 1,000 people in the U.S. To learn more about Biotest Pharmaceuticals and our Plasma Centers and the difference we make in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com and www.biotestplasma.com.
SOURCE Biotest Pharmaceuticals
